Titre : | Higher average potency across the United States is associated with progression to first cannabis use disorder symptom (2019) |
Auteurs : | B. J. ARTERBERRY ; H. TRELOAR PADOVANO ; K. T. FOSTER ; R. A. ZUCKER ; B. M. HICKS |
Type de document : | Article : Périodique |
Dans : | Drug and Alcohol Dependence (Vol.195, February 2019) |
Article en page(s) : | 186-192 |
Langues: | Anglais |
Discipline : | EPI (Epidémiologie / Epidemiology) |
Mots-clés : |
Thésaurus géographique ETATS-UNISThésaurus mots-clés CANNABIS ; TETRAHYDROCANNABINOL ; SYMPTOME ; ETUDE LONGITUDINALE ; FACTEUR PREDICTIF ; FACTEUR DE RISQUE ; TYPE D'USAGE |
Résumé : |
Objective: To determine if higher potency cannabis is associated with earlier progression to regular cannabis use, daily cannabis use, and cannabis use disorder symptom onset.
Methods: Data sources were the Michigan Longitudinal Study, an ongoing prospective, high-risk family study investigating the course and predictors for substance use disorders among youth beginning prior to school entry and time-parallel national average trends in delta-9-tetrahydrocannabinol (i.e., psychoactive compound in cannabis). The national average trends in delta-9-tetrahydrocannabinol were used to estimate potency level for the individual. Only cannabis users were included in analyses (n = 527). Results: Cox regression showed an increased risk of progression from cannabis initiation to cannabis use disorder symptom onset by 1.41 times (p Conclusions: This study provides prospective evidence suggesting higher potency cannabis, on average in the U.S., increases risk for onset of first cannabis use disorder symptom. Development of guidelines regarding cannabis potency is critical for reducing the costs associated with negative health outcomes. Highlights: Risk to faster cannabis use disorder symptom onset increased at higher potency levels. Initiating at 4.9% showed 88% risk for symptom onset within a year. Initiating at 12.3% showed 4.85 times higher risk for symptom onset within a year. Potency did not predict progression to regular or daily cannabis use. |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : | Department of Psychology, Iowa State University, Ames, IA, USA |
Accueil